Non-Small Cell Lung Cancer News

Frontline Lorlatinib Induces 90% Response in ALK+ NSCLC - OncLive



OncLive
 
Frontline Lorlatinib Induces 90% Response in ALK+ NSCLC 
OncLive
Lorlatinib induced an objective response rate (ORR) of 90% (27/30; 95% CI, 74-98) in treatment-na´ve patients with ALK-positive non?small cell lung cancer (NSCLC). Intracranial ORR (IC-ORR) was 75% (6/8; 95% CI, 35-97) in this population, according to ...
Pfizer next-gen ALK inhibitor could ease lung cancer burden BioPharma Dive
Pfizer's lorlatinib impresses in Phase II lung cancer trial PharmaTimes
Pfizer's P2 trial for lung cancer drug shows 90% effectiveness Korea Biomedical Review
Market Exclusive 
all 6 news articles » 


Upfront Immunotherapy for NSCLC - OncLive



OncLive
 
Upfront Immunotherapy for NSCLC 
OncLive
Suresh S. Ramalingam, MD: Hello, and thank you for joining this OncLive« Peer Exchange« discussing the ?Global Outlook on Advanced Nonsquamous NSCLC.? As medical oncologists, we witnessed a sea change in the way advanced lung cancer is ...

and more » 


FDA Grants Priority Review to Durvalumab for Locally Advanced Unresectable NSCLC - OncLive



OncLive
 
FDA Grants Priority Review to Durvalumab for Locally Advanced Unresectable NSCLC 
OncLive
The FDA has granted a priority review to a supplemental biologics license application (sBLA) for durvalumab (Imfinzi) for the treatment of patients with stage III, unresectable non?small cell lung cancer (NSCLC), based on positive progression-free ...

and more » 


Socioeconomic factors influence non-small cell lung cancer survival - Healio



PR Web (press release)
 
Socioeconomic factors influence non-small cell lung cancer survival 
Healio
Socioeconomic factors, such as lower education and median income, significantly influenced survival among patients with non-small cell lung cancer, according to study results presented at International Association for the Study of Lung Cancer World ...
Inivata Highlights New Clinical Data on InVision(TM) ctDNA Liquid Biopsy Platform in advanced NSCLC at WCLC 2017 GlobeNewswire (press release)
World Conference on Lung Cancer Tuesday Press Conference: Evidence to Support Innovative Lung Cancer ... Markets Insider
Durvalumab in Stage III Lung Cancer: 'An Important Advance' Medscape
PR Web (press release)  -DeathRattleSports.com 
all 14 news articles » 


Where there's smoke... - Nature.com



Nature.com
 
Where there's smoke... 
Nature.com
A new study, recently published in Cancer Cell, demonstrates that chronic smoking elicits progressive changes in histone and DNA methylation patterns, which can sensitize lung epithelial cells to form tumours in response to a single oncogenic event.

 


Ramucirumab Associated With OS Benefit in Aggressive NSCLC - OncLive



OncLive
 
Ramucirumab Associated With OS Benefit in Aggressive NSCLC 
OncLive
Ramucirumab (Cyramza) plus docetaxel demonstrated an overall survival (OS) benefit versus placebo plus docetaxel in patients with advanced non?small cell lung cancer (NSCLC) whose disease rapidly progressed on first-line therapy, according to an ...

 


MET/EGFR Combo Effective for Advanced NSCLC - OncLive



OncLive
 
MET/EGFR Combo Effective for Advanced NSCLC 
OncLive
The combination of osimertinib (Tagrisso) and the MET inhibitor savolitinib showed signs of efficacy for pretreated patients with MET-positive, EGFR-mutant non?small cell lung cancer (NSCLC), regardless of prior treatment with a T790M-directed therapy, ...
Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC Cancer Therapy Advisor

all 6 news articles » 


FDA grants priority review to Imfinzi for advanced non-small cell lung cancer - Healio



pharmaphorum (blog)
 
FDA grants priority review to Imfinzi for advanced non-small cell lung cancer 
Healio
The FDA granted priority review to durvalumab for the treatment of patients with locally advanced unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy. The supplemental biologics ...
AstraZeneca files Imfinzi for groundbreaking lung cancer use pharmaphorum (blog)
AstraZeneca's Imfinzi gets speedy US review for lung cancer PharmaTimes
US FDA Accepts Supplemental Biologics License Application for IMFINZI Business Wire (press release)
Proactive Investors UK  -DIGITALLOOK  -Markets Insider 
all 11 news articles » 


Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA ... - PR Newswire (press release)



Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA ... 
PR Newswire (press release)
INDIANAPOLIS, Oct. 16, 2017 /PRNewswire/ -- New subgroup analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 REVEL trial of CYRAMZA« (ramucirumab) in advanced non-small cell lung cancer (NSCLC) was presented today at the 18th World ...
Eli Lilly & Co. (LLY) Announces New Phase 3 REVEL trial of CYRAMZA Data at 18th World Conference on Lung Cancer StreetInsider.com

all 3 news articles » 


Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a ... - Dove Medical Press



Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a ... 
Dove Medical Press
Background: Treatment failure frequently occurs in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) who respond to EGFR tyrosine kinase inhibitors initially. This retrospective study tried to investigate ...